In a phase 1/1b trial (NCT02009449), one ovarian cancer patient and 22 pancreatic cancer patients were recruited to evaluate the safety and efficacy of pegilodecakin (pegylated IL-10) as monotherapy, and the results showed that patients did not have obvious clinical responses [110]. The gene discussed is IL10; the disease is ovarian carcinoma.